A total of 384 scFv (Figure 2B) identified in initial assays were re-assayed against IgM obtained from a pool of 8 early stage I adenocarcinoma patients and IgM obtained from a pool of 8 normal human serum samples to identify 9 scFv that preferentially bound IgM from early stage I lung cancer patients in comparison to normal patients (with p<0.05) as it is shown in Figure 2B for three scFvs – B6, J4 and E3,. The gene discussed is CD40LG; the disease is lung cancer.